ERAS
Price
$2.76
Change
-$0.10 (-3.50%)
Updated
Nov 19 closing price
Capitalization
814.25M
119 days until earnings call
Intraday BUY SELL Signals
EYPT
Price
$14.28
Change
+$0.32 (+2.29%)
Updated
Nov 19 closing price
Capitalization
1.18B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs EYPT

Header iconERAS vs EYPT Comparison
Open Charts ERAS vs EYPTBanner chart's image
Erasca
Price$2.76
Change-$0.10 (-3.50%)
Volume$2.05M
Capitalization814.25M
EyePoint Pharmaceuticals
Price$14.28
Change+$0.32 (+2.29%)
Volume$1.4M
Capitalization1.18B
ERAS vs EYPT Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
EYPT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. EYPT commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ERAS: $2.77 vs. EYPT: $14.28)
Brand notoriety: ERAS and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 113% vs. EYPT: 102%
Market capitalization -- ERAS: $814.25M vs. EYPT: $1.18B
ERAS [@Biotechnology] is valued at $814.25M. EYPT’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ERAS and EYPT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • EYPT’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ERAS and EYPT are a bad buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а +4.34% price change this week, while EYPT (@Biotechnology) price change was +19.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

EYPT is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($1.18B) has a higher market cap than ERAS($814M). EYPT YTD gains are higher at: 91.678 vs. ERAS (10.159). ERAS has higher annual earnings (EBITDA): -135.93M vs. EYPT (-172.05M). ERAS has more cash in the bank: 301M vs. EYPT (256M). EYPT has less debt than ERAS: EYPT (21.8M) vs ERAS (49.4M). EYPT has higher revenues than ERAS: EYPT (51.9M) vs ERAS (0).
ERASEYPTERAS / EYPT
Capitalization814M1.18B69%
EBITDA-135.93M-172.05M79%
Gain YTD10.15991.67811%
P/E RatioN/AN/A-
Revenue051.9M-
Total Cash301M256M118%
Total Debt49.4M21.8M227%
FUNDAMENTALS RATINGS
EYPT: Fundamental Ratings
EYPT
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
PROFIT vs RISK RATING
1..100
72
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
13
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASEYPT
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 1 day ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 16 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
EYPT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVNQX50.730.28
+0.56%
Invesco Nasdaq 100 Index R6
FUNYX39.33N/A
N/A
Victory Pioneer Fundamental Growth Y
BERCX17.45N/A
N/A
Carillon Chartwell Mid Cap Value I
QQMNX21.87N/A
N/A
Federated Hermes MDT Market Neutral IS
JFEIX40.79-0.30
-0.73%
JPMorgan Europe Dynamic L

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with OCUL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-3.32%
OCUL - ERAS
53%
Loosely correlated
+2.81%
XNCR - ERAS
52%
Loosely correlated
-1.62%
EYPT - ERAS
49%
Loosely correlated
+2.29%
RVMD - ERAS
48%
Loosely correlated
-0.04%
IMTX - ERAS
47%
Loosely correlated
N/A
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+2.29%
OCUL - EYPT
62%
Loosely correlated
+2.81%
LYRA - EYPT
58%
Loosely correlated
-4.93%
ATHE - EYPT
54%
Loosely correlated
N/A
IDYA - EYPT
50%
Loosely correlated
-1.72%
BEAM - EYPT
50%
Loosely correlated
-4.24%
More